Vaccine Economic Impact
Billions of dollars saved
Most economic studies of rotavirus vaccines conducted in countries throughout the world and at different levels of development have found rotavirus vaccination to be cost-effective. This is true even under the assumption that Gavi-supported countries pay the full Gavi price for the vaccine (with no subsidies) and wealthier countries pay prevailing market prices.
Rotavirus Vaccines are Cost-Effective
Cost-effectiveness is dependent on a number of variables, including vaccine price, relative coverage, herd protection, vaccine effectiveness, the number of deaths and hospitalizations, and rate of waning protection.11 Cost-effectiveness analyses can also be used to estimate the break-even price of the vaccine. This is the price at which the saving in treatment costs are equal to the cost of the vaccination program.
1. Anwari, P., et al., Potential impact and cost-effectiveness of rotavirus vaccination in Afghanistan. Vaccine 2017, 10 (58).
2. Bar-Zeev, N., et al., Cost-Effectiveness of Monovalent Rotavirus Vaccination of Infants in Malawi: A Postintroduction Analysis Using Individual Patient–Level Costing Data. Clinical Infectious Diseases 2016, 62 (suppl 2), S220–S228.
3. Sigei, C., et al., Cost-effectiveness of rotavirus vaccination in Kenya and Uganda. Vaccine 2015, 33 Suppl 1, A109–18.
4. Suwantika, A. A.; Tu, H. A.; Postma, M. J., Cost-effectiveness of rotavirus immunization in Indonesia: taking breastfeeding patterns into account. Vaccine 2013, 31 (32), 3300–7.
5. Pecenka, C., et al., Impact and cost-effectiveness of rotavirus vaccination in Bangladesh. Vaccine 2017, 35 (32), 3982–3987.
6. Patel, H. D.; Roberts, E. T.; Constenla, D. O., Cost-effectiveness of a new rotavirus vaccination program in Pakistan: a decision tree model. Vaccine 2013, 31 (51), 6072–8.
7. Nonvignon, J., et al., Cost-effectiveness of rotavirus vaccination in Ghana: Examining impacts from 2012 to 2031. Vaccine 2017.
8. Koksal, T., et al., Cost-effectiveness of rotavirus vaccination in Turkey. J Microbiol Immunol Infect 2017, 50 (5), 693–699.
9. Javanbakht, M., et al., Cost-effectiveness analysis of the introduction of rotavirus vaccine in Iran. Vaccine 2015, 33 Suppl 1, A192–200.
10. Aidelsburger, P., et al., Cost-effectiveness of childhood rotavirus vaccination in Germany. Vaccine 2014, 32 (17), 1964–74
11. Clark, A., et al., TRIVAC decision-support model for evaluating the cost-effectiveness of Haemophilus influenzae type b, pneumococcal and rotavirus vaccination. Vaccine, 2013. 31 Suppl 3: p. C19-29.
12. Gavi Secretariat and Partners, Gavisupported rotavirus vaccine profiles to support country decision making. 2019 March [cited 2019 April]; Available from: https://www.gavi.org/library/gavidocuments/supply-procurement/rotavirus -vaccine-profiles/.
13. World Health Organization, Vaccine Purchase Data (V3P); 2017
14. Pan American Health Organization. Expanded Program of Immunization Vaccine Prices for Year 2019. 2019; Available from: https://www.paho.org/hq/index.php ?option=com_docman&view=download &category_slug=vaccines-9979&alias =47514-revolving-fund-vaccine-prices -2019&Itemid=270&lang=en
15. Reyes, J. F., et al., Beyond expectations: Post-implementation data shows rotavirus vaccination is likely cost-saving in Australia. Vaccine 2017, 35 (2), 345–352.
16. CDC, CDC Vaccine Price List. 2019.
17. Tate, J. E., et al., Rotavirus disease burden and impact and cost-effectiveness of a rotavirus vaccination program in Kenya. J Infect Dis 2009, 200 Suppl 1, S76–84.
18. Smith, E.R., et al., Cost-effectiveness of rotavirus vaccination in Bolivia from the state perspective. Vaccine, 2011. 29(38): p. 6704–11
19. Milne, R.J. and K. Grimwood, Budget impact and cost-effectiveness of including a pentavalent rotavirus vaccine in the New Zealand childhood immunization schedule. Value In Health, 2009. 12(6): p. 888–98.
20. Al-Aidaroos, A. Y. A., et al., Economic assessment of rotavirus vaccination in Saudi Arabia. J Infect Public Health 2017, 10 (5), 564–571.